Browse News
Filter News
Found 522,207 articles
-
8 Questions Not to Ask in the Job Interview
10/19/2018
It’s prudent to be aware of certain types of questions that -- while perhaps valid -- just don’t belong in this particular professional encounter and, in fact, could harm your candidacy and reflect negatively on your reputation if asked. -
Gene Therapy, Gene Editing and Immuno-Oncology Creating Thousands of New Job Opportunities
10/19/2018
The U.S. Bureau of Labor Statistics predicts a 7 percent increase in jobs for biomedical engineers and a 13 percent increase in medical scientists. -
Multiple biotech companies are scheduled to release their quarterly reports next week. BioSpace takes a quick look at some these companies and the announcements they have made through 3Q2018.
-
19 (at Least!) of TIME Magazine’s 50 Most Influential Healthcare People Have Biopharma Ties
10/19/2018
TIME Magazine came out with a list of the 50 most influential people in healthcare, dubbed The Health Care 50. A look through the list shows just how many ties and connections—as well as influence—this group has on the biopharma industry. -
Opioid Drugmakers Call for Specificity in Cases of Harm in Government Lawsuits Filed Against Them
10/19/2018
As more and more lawsuits are filed by state and local governments over the opioid epidemic, drugmakers are fighting back in court by demanding the allegations include specifics on how the companies are to blame. -
October 19 Research Roundup: Dementia, Frankenstein Proteins, and Epigenetic Sperm Changes
10/19/2018
There are plenty of great scientific research stories out this week. Here’s a look at just a few of them. -
Federal Government Cracks Down on Stem Cell Clinics That Offer Cures for Autism, Blindness and Ot...
10/19/2018
The U.S. Federal Trade Commission has cracked down on clinics that are making claims that certain stem cell therapies can treat a number of serious diseases such as Parkinson’s disease, autism, macular degeneration, cerebral palsy, multiple sclerosis, and heart attacks. -
The trial was evaluating MM-121 in combination with docetaxel, a chemotherapy drug, in patients with heregulin positive non-small cell lung cancer (NSCLC).
-
Proteostasis Therapeutics' Double and Triple-Combo CF Drugs Possible Threat to Vertex Dominance
10/19/2018
Proteostasis Therapeutics announced positive preliminary data from its ongoing Phase I clinical trial of PTI-808 and PTI-801 in cystic fibrosis (CF). Despite it being an early-stage trial and preliminary data, company shares exploded upward by 301 percent, with more than 44 million shares trading... -
Part of the Trump Administration and the U.S. Food and Drug Administration (FDA)’s strategy to push down drug prices is to develop ways to increase competition. As such, the agency launched a Drug Competition Action Plan that has several components.
-
Shares of Clovis Oncology are up more than 7 percent in premarket trading after the company announced positive results from a mid-stage clinical trial that showed patients treated with Rubraca achieved a 44 percent objective response rate in some patients with metastatic castration resistant pros...
-
A summary of IPOs from companies in the biotech and pharma world since Oct. 1, 2018.
-
Aurora Cannabis Files Early Warning Report in Connection with TGOD Holding
10/19/2018
Aurora Cannabis Inc. ("Aurora" or the "Company") (TSX: ACB) (NYSE: ACB) (Frankfurt: 21P; WKN: A1C4WM), announced today that it has filed an early warning report in respect to its holdings in The Green Organic Dutchman Holdings Ltd. ("TGOD"), a company with a head office at 6025 Airport Road, Building A – Suite 301, Mississauga Ontario L4V 1E3.
-
IDT showcases CRISPR expertise in Europe
10/19/2018
As an advocate for the genomics age, Integrated DNA Technologies (IDT), will showcase its renowned CRISPR expertise at a series of European-focused events.
-
FDA Approves Asthma Indication for Dupixent® (dupilumab)
10/19/2018
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced the U.S. Food and Drug Administration has approved Dupixent® (dupilumab
-
BERG to Present New Data Describing Details on Progress of its Oncology Portfolio and Precision Medicine Applications at the European Society for Medical Oncology 2018 Congress
10/19/2018
BERG LLC, a Boston-based biopharmaceutical company that merges biology with technology to map the nature of diseases, today announced the presentation of three posters on the progression of its oncology and artificial intelligence (AI)/Biomarker portfolio at the European Society of Medical Oncology (ESMO) 2018 Annual Congress
-
LumiThera, Inc. Selected to Present at the Ophthalmology Innovation Summit 2018 at the American Academy of Ophthalmology, Chicago, IL
10/19/2018
LumiThera® Inc., a commercial-stage medical device company focused on developing photobiomodulation (PBM) therapies for ocular disorders and disease, today announced that it will present at the Ophthalmology Innovation Summit at the American Academy of Ophthalmology (OIS@AAO) meeting on October 25, 2018, in Chicago, IL.
-
U.S. Sen. Heinrich Among Dignitaries Expected for Navajo Nation CPC
10/19/2018
U.S. Sen. Martin Heinrich is among the dignitaries expected to attend the International Water, Sanitation and Hygiene (IWSH) Foundation's 2018 Community Plumbing Challenge, which begins Monday in Thoreau, New Mexico.
-
SI-BONE Announces Closing of Initial Public Offering and Exercise in Full of Underwriters' Option to Purchase Additional Shares
10/19/2018
SI-BONE, Inc. (Nasdaq: SIBN) ("SI-BONE"), a medical device company that pioneered the minimally invasive surgical treatment of the sacroiliac joint with the iFuse Implant System®, today announced the closing of its initial public offering of 8,280,000 shares of common stock, at a price to the public of $15.00 per share,
-
FDA Approves Label Update for Genentech’s Rituxan (Rituximab) in Two Rare Forms of Vasculitis
10/19/2018
Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the U.S. Food and Drug Administration (FDA) has approved an update to the Rituxan®